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ABSTRACT 
Oral squamous cell carcinoma represents more than 90% head and neck cancers 
with high incidence rate and morbidity. To date, little is known about the molecular 
mechanisms responsible for OSCC initiation and progression to advanced disease. Thus, 
identifying key pathways involved in OSCC pathobiology is likely to lead to the 
identification of new druggable targets and future anti-cancer therapies.  
Work from our laboratory has linked the metabolic pathway of protein N-
glycosylation with OSCC biology. Specifically, overexpression of the first N-
glycosylation gene, DPAGT1, in human OSCC tumor specimens was shown to be 
associated with aberrant activation of canonical Wnt signaling and inhibition of mature 
E-cadherin junctions. The purpose of this study was to examine how increased N-
glycosylation was associated with OSCC growth and metastatic properties in cellular and 
murine models. We show that high level of DPAGT1 expression correlates with increased 
cell surface modification of malignant OSCC HSC-3 cells with complex N-glycans. 
Further, HSC-3 cells are hypersenitive to the N-glycosylation inhibitor, tunicamycin, 
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suggesting that aggressive properties of OSCC cells depend, in part, on the N-
glycosylation pathway. Lastly, we show that orthotopic HSC-3 cell-derived tumor 
xenografts are inhibited by tunicamycin both in overall growth and metastases, indicating 
that targeting DPAGT1 and N-glycosylation may represent a new strategy for the 
treatment of OSCC in human patients. 
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Introduction 
Oral squamous cell carcinoma (OSCC) accounts for more than 90% of head and 
neck cancers and ranks as the sixth most common cancer worldwide (Vigneswaran et al 
2014). Approximately 630,000 new patients diagnosed annually resulting in more than 
350,000 deaths every year (Vigneswaran et al 2014). OSCC initiation and progression is 
has been shown to be associated with dysregulation in multiple cellular signaling 
pathways (Agrawal et al., 2011; Stransky et al., 2012; Lui et al., 2013), and recent studies 
mapped genomic alterations in OSCC (Cancer Genome Network, 2015). These studies 
are beginning to provide insights regarding the dysregulated signals contributing to the 
onset and progression of OSCC, but much remains poorly understood. Notably, very little 
is known about the early stages of cancer onset or of the signals that drive aggressive 
traits and/or resistance to current therapeutics.   
To date, numerous human OSCC cell lines have been established. However, since 
the growth patterns and invasive characteristics of these cell lines differ from each other, 
not all are suitable for modeling OSCC biology in vitro and in vivo. In 1982, Gioanni and 
colleagues established the CAL27 OSCC cell line from a tumor tissue of a 56-year-old 
Caucasian male with poorly differentiated squamous cell carcinoma of the middle of the 
tongue (Gioanni et al 1982). In contrast, the HSC-3 cell line is one of the most often 
utilized cell lines for an in vivo modeling of OSCC and significant amount of information 
is known about this cell line. HSC-3 cell line was first established in Japan from cells 
derived from a 64-year-old male patient with a primary moderately differentiated tumor 
located in the tongue with lymph nodes metastasis (Momose et al., 1989). 
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The metabolic pathway of protein N-glycosylation has long been implicated in 
neoplasia, with the gene that function at its first committed step, DPAGT1, playing a 
central role in tumor development and spread (Pinho et al 2015). DPAGT1 encodes the 
dolichol-phosphate-dependent N-acetylglucosamine-1-phosphate transferase, GPT, which 
catalyzes the first step in lipid linked oligosaccharide precursor LLO synthesis that 
involves the transfer of GlcNAc-P from UDP-GlcNAc to dolichol-P to produce dolichol-
PP-GlcNAc (Kornfeld and Kornfeld 1985; Robbins and Runge 1986; Volpe et al 1987; 
Aebi, 2013). The GPT enzyme functions at a control point for the overall N- 
glycosylation pathway, as small changes in its expression give rise to robust changes in 
the expression of downstream N-glycosylation genes in the ER and the Golgi 
(Mendelsohn et al. 2005)(Fig.1). DPAGT1 is essential for normal development and 
differentiation in yeast(Kukuruzinska & Robbins, 1987) and in mammalian cells (Eckert 
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et al., 1998; Lehrmans, Zhu, & Khounlo, 1988; Scocca & Krag, 1990). In humans, 
mutations in DPAGT1 that result in a significant reduction in GPT activity give rise to 
congenital disorders and early mortality (Carrera et al. 2012; Timal et al. 2012) and 
deletion of DPAGT1 in mice leads to pre-implantation mortality (Marek et al. 1999). 
We have shown that DPAGT1 itself is a target of Wnt/β-catenin signaling, and 
that it functions in a positive feedback loop with Wnt/β-catenin signaling (Sengupta et al 
2010)(Fig. 2). In addition, DPAGT1-driven increased N-glycosylation in OSCC inhibits 
the formation of mature E-cadherin junctions, thus abolishing the ability of E-cadherin to 
attenuate Wnt/β-catenin and DPGAT1 expression via a negative feedback mechanism 
(Singupta et al. 2013; Varelas et al 2014) (Fig. 2).  
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Protein N-glycosylation is a highly conserved and essential post-translational 
modification with roles in development and differentiation (Marek et al. 1999; Stanely 
and Cummings. 2009; Pinho and Reis. 2015). N-glycans control the activity of a wide-
range of proteins, including the surface presentation and activity of receptor tyrosine 
kinases, such as EGFR, FGFR and PDGFR, known to promote cell proliferation and 
survival (Contessa et al 2008; Itkonen et al 2015). Further, N-glycosylation has been 
shown to be essential for the surface presentation of proteins implicated in regulating 
cellular plasticity including CD44, CD24, CD29 and CD133 among others (Bartolazzi et 
al 1996, Lakshminarayan et al 2014). In addition to the acknowledged roles of N-glycans 
in development, N-glycosylation dysregulation has been linked to various diseases 
including cancer (Varki et al. 2009; Ho et al 2016).  
Published and preliminary studies from our laboratory have shown that increased 
activity of the N-glycosylation pathway has a key role in promoting OSCC pathogenesis 
(Jamal et al 2012; Sengupta et al 2010, Sengupta et al, 2012). The DPAGT1 gene, which 
encodes the rate limiting N-glycosylation enzyme, GPT, is aberrantly induced in OSCCs 
(Nita-Lazar et al 2009; Varelas et al 2014). We have shown that DPAGT1 acts as a key 
driver of Wnt/β-catenin signaling (Sengupta et al 2013). Furthermore, high DPAGT1 
expression represses E-cadherin-mediated cell adhesion, promoting the transition 
between epithelial and mesenchymal states (Sengupta et al 2013). On the other hand, 
reduced expression of DPAGT1 is associated with increased cell adhesion and cellular 
differentiation (Nita-Lazar et al. 2009, 2010). Also, metastatic phenotypes in OSCC cells 
in vitro and high DPAGT1 expression are associated with upregulated CD44 in human 
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OSCC specimens in vivo (Geng et al 2013). Indeed, many epithelial cancers display loss 
of E-cadherin, and E-cadherin is commonly downregulated in tumors by transcriptional 
repressors such as SLUG, SNAIL, TWIST and ZEB (Wang et al. 2011; Wu et al. 2012).  
For cells to become metastatic, they have to lose some of the intercellular 
junctions and acquire migratory characteristics in order to detach from the primary tumor, 
invade the surrounding stroma and travel to distant sites (Martin et al 2013). Indeed, we 
have recently shown that such an unchecked amplification of the DPAGT1-Wnt/β- 
catenin feedback loop and loss of E-cadherin adhesion leads to the activation of a key 
downstream pro-tumorigenic pathway, the non-canonical Wnt/planar cell polarity 
(Wnt/PCP) pathway, via dramatic increases in the expression of a pro-metastatic 
glycoprotein, collagen triple helix repeat-containing 1 (CTHRC1) (Liu et al 2013).  
Numerous studies highlight pivotal roles for Wnt/β-catenin in cancer and there is 
substantial evidence that the outgrowth of metastatic lesions and cancer cells is promoted 
by Wnt pathway components (Giles, Van Es, & Clevers, 2003); Yang. 2012; Zhou. 2009; 
Zham et al. 2016; Malladi et al., 2016; Tammela et al., 2017; (Lien and Fuchs, 2014)). 
Our previous results have linked the metabolic pathway of protein N-glycosylation with 
OSCC biology; specifically, overexpression of the first N-glycosylation gene, DPAGT1, 
in human OSCC tumor specimens was shown to be associated with aberrant activation of 
canonical Wnt signaling and inhibition of mature E-cadherin junctions (Nita-Lazar et al. 
2009; Jamal et al 2012; Liu et al. 2013; Varelas et al. 2014). The goal of this study was to 
examine further how increased N-glycosylation was associated with OSCC growth and 
metastatic properties in cellular and murine models. 
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MATERIALS AND METHODS 
CELL CULTURE AND PREPARATION OF CELL LYSATES 
CAL27 and HSC-3 cells were maintained in DMEM (Invitrogen) and 
supplemented with 10% fetal bovine serum, penicillin and streptomycin. After 48h, the 
media were changed and cells were divided into several plates and further expanded. 
Media were changed every 2–3 days. After 2 weeks, cells were processed for preparation 
of total cell lysates. For total cell lysates, CAL 27 and HSC-3 cells were extracted with 
600 μl of ice- cold Triton X-100/β-octylglucosidase buffer (10 mM imidazole, 100 mM 
NaCl, 1 mM MgCl2, 5 mM Na2EDTA, 1% Triton X-100, 0.87 mg/ml β-
octylglucosidase) containing 50 μg/ml aprotinin, 25 μg/ml soybean trypsin inhibitor, 100 
μM benzamidine, 5 μg/ml leupeptin and 0.5 μM PMSF. Protein concentrations were 
determined using BCA protein assay (Pierce). 
 
REAGENTS 
Monoclonal antibodies to E-cadherin, β-catenin, γ-catenin, α-catenin, CD44 and 
IgG isotype controls were obtained from BD Transduction Laboratories. Polyclonal 
antibodies. Monoclonal antibodies to Myc tag, GSK-3β and polyclonal antibody to 
pGSK- 3β were from Cell Signaling Technology. Monoclonal antibody ABC were from 
Millipore, respectively. Monoclonal antibody to pan-actin Ab-5 was from NeoMarkers 
while polyclonal antibody to GAPDH was from Sigma. Rabbit polyclonal antibody to 
hamster GPT was prepared commercially (Covance Research Products, Inc.). 
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TISSUE SPECIMEN 
All studies with surgical OSCC specimens were approved by the Institutional 
Review Board at the Boston University Medical Campus. Fresh tissues were obtained 
from patients with moderately differentiated to poorly differentiated OSCC of the tongue, 
maxillary gingiva, and floor of mouth. Regions of OSCC and adjacent epithelia (AE), 
defined by an on-site pathology analysis, were snap-frozen at −80°C. Tissues were 
divided for biochemistry, and immunofluorescence staining. OCT-embedded fresh tumor 
tissues were used for the preparation of frozen sections (5 μm). For biochemical analyses, 
total tissue lysates (TTLs) from AE and OSCC were prepared by extraction with Triton 
X-100/β-octyl-glucoside buffer as described previously. Protein concentrations were 
determined using the BCA assay (Pierce). 
 
IMMUNOFLUORESCENCE IMAGING 
For immunofluorescence analyses, cells were plated in chamber slides at a density 
of 5–6 × 103/cm2. Direct immunofluorescence, Cal27, HSC-3, normal canine epithelial 
MDCK cells and  murine fibroblasts were seeded in  Costar® 24 well cell culture cluster.  
The cells were grown to 70%  confluence, treated with 0.5μg/ml of  tunicamycin for 24 
hours in 37°C.  Cells were then stained on ice with  PHA-L Alexa Fluor® 488 conjugate at  
a concentration of 10μg/ml for 30 minutes then fixed with 4% paraformaldehyde. Cells 
were imaged using an epifluorescence microscope with the SPOT Digital Microscope 
Camera software. Indirect immunofluorescence analysis was carried out with a Zeiss  
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LSM510 META confocal microscope; settings were fixed to the most highly stained 
sample and all other images were acquired at those settings.  
 
FLOW CYTOMETRY 
CAL27 and HSC-3 cells were collected by trypsinization of monolayer cultures 
followed by centrifugation. After surface labeling with lectins PHA-L and ConA, the 
cells were resuspended in 1 ml of PBS at RT, transferred to 4 ml of absolute ethanol and 
placed at – 20°C for 5-15 min after which they were resuspended in 5 ml of PBS for 15 
min. Next, the cells were treated with ribonuclease (1 mg/ml) for 5 min at RT and 
resuspended in 200 μl of 3 μM PI solution. Cells were phenotyped based on their PHA-L 
and ConA lectin binding specificities by Flow Cytometry and sorted by FACS (Becton 
Dickinson). Analysis was performed using CellQuest Pro software and ImageJ software. 
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RESULTS 
 
Aggressive OSCC cells display aberrant activation of protein N-glycosylation in 
vitro  
N-glycans have been used as markers of embryonic stem cells and carcinoma cells 
(Lanctot, Gage, & Varki, 2007; Stanely & Cummings. 2009). Furthermore, changes in N-
glycans structures have been shown to modulate the biological fate and function of cell 
surface N-glycoprotein receptors that decorate embryonic and cancer stem cells 
(Bieberich 2014). For instance, primitive cell surface markers CD44 and CD133 require 
N-glycosylation for membrane presentation and activity (Stanley and Cummings 2009; 
Bartolazzi et al 1996; Lakshminarayan et al 2014). Our studies have shown that DPAGT1 
is a key regulator of protein N-glycosylation, which determines the N-glycosylation 
status of glycoproteins and impacts their stability and membrane localization (Sengupta 
et al 2012, Jamal et al 2012). Also, DPAGT1 is co-regulated with N- glycosylation genes 
that function downstream in the pathway in the Golgi. In particular, we have shown that 
even a modest 2.5-fold increase in the DPAGT1 transcript levels leads to a robust 11-fold 
upregulation of MGAT5 mRNA, an N-glycosylation gene that functions in the Golgi in 
the modification of glycoproteins with complex, highly branched N-glycans, and which is 
frequently associated with metastasis (Sengupta et al 2010). Thus, it is likely that an 
aberrant increase in DPAGT1 expression in OSCC will be a major determinant of surface 
presentation of N-glycoprotein markers, such as CD24, CD29 and CD44. Furthermore, 
since DPAGT1 and Wnt/β-catenin function in a positive feedback loop, increased 
expression of DPAGT1 will drive inappropriate activation of Wnt/β-catenin signaling, 
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shown to be a key pathway defining the cancer initiating state in murine salivary gland 
tumors and in human head and neck cancers (Wend et al, 2013). Indeed, our previous 
studies have aligned aberrantly high expression of DPAGT1 with the loss of E-cadherin 
adhesion and inappropriate activation of the Wnt/b-catenin signaling pathway (Nita-
Lazar et al., 2009; Jamal et al., 2012). Further, they provided intial evidence for the 
association of DPAGT1 with epithelial-to-mesenchymal transition (EMT), cellular 
discohesion and invasion into the underlying tumor stroma [(Nita-Lazar et al., 2009; Liu 
et al., 2013)(reviewed in Varelas et al., 2014)]. One mechanism via which DPAGT1 was 
shown to promote EMT involved inhibition of GSK3β activity by increased 
phosphorylation via the PI3K pathway, leading to reduced degradation of β-catenin and 
increased levels of its active species (ABC) (Sengupta et al., 2013).  Additionally, we 
have shown that DPAGT1 and Wnt/b-catenin signaling collaborate to induce a 
prometastatic protein, CTHRC1, likely to contribute to cell invasion in OSCC via 
activation of the Wnt/planar cell polarity pathway (Liu et al., 2013). 
In this study, we examined further the role of DPAGT1 and N-glycosylation in 
aggressive OSCC cell phenotypes in two cellular models vitro and in a nude mouse 
model in vivo. We utilized two cell lines with distinct characteristics, a non-matastatic 
CAL27 cell line and an aggressive HSC-3 cell line. Specifically, in an orthotopic mouse 
model of tongue cancer, CAL27  cells form tumors that do not metastasize while in  
contrast HSC-3 cells form tumors that metastasize to different sites resembling the sites 
of metastases in humans (Matsui et al, 1998). Immunoblot analyses of GPT, ABC, 
pGSK3β  and prometastatic DPAGT1-induced protein, CTHRC1, revealed upregulation 
of these proteins in metastatic HSC-3 cells (Table 1). Indirect immunofluorescence 
		 11	
analysis of CAL27 and HSC-3 cells revealed increased expression of GPT in HSC-3 cells 
that coincided with greater nuclear localization of β-catenin. This correlates with our 
observation that N- glycosylation was increased in HSC-3 cells. In HSC-3 cells, β-
catenin was found to be more nuclear, perinuclear and cytoplasmic, while in CAL27 cells 
it was more localized to the membrane. This indicates that both E-cadherin and β-catenin 
form immature junctions in metastatic HSC-3 cells to a greater extent than non-metastatic 
CAL27 (Fig. 3). 
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Fig. 3. Immunofluorescence analysis of GPT using the SPOT Digital 
Microscope Camera shows that DOAGT1 is prominently expressed in 
CAL27 and HSC-3 cells, with increased fraction in HSC-3. Β-catenin is 
found to be more cytoplasmic in HSC-3 cells. 
							CAL27		 	 	 HSC-3		
							β-c
at
en
in
											
			GPT	
	
Table. 1. Selected molecular markers upregulated in metastatic HSC-3  
cells 
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Metastatic HSC-3 cells exhibit increased binding of PHA lectin compared to non- 
metastatic CAL27 cells 
Different lectins were used to ultimately isolate cells that differ in their surface 
presentation of N-glycans by FACS. Lectins, are carbohydrate-binding proteins, with 
high selectivity for specific sugar moieties. Due to their selectivity, they have been used 
as tools for determining different carbohydrate repertoires on cells. They recognize and 
bind glycan structures either in solution or linked to glycoproteins, glycolipids and 
proteoglycans (Ielasi et al, 2016). To examine differences in carbohydrate presentation on 
CAL27 and HSC-3 cells, we used PHA-L and ConA lectins conjugated with Alexa Fluor 
488 and FITC fluorochromes, respectively. ConA preferentially binds exposed mannose 
and glucose residues, and thus it selects for glycoproteins modified with high-
mannose/hybrid N-glycans. In contrast, PHA-L is specific for complex, branched 
oligosaccharides. This approach allowed us to screen for cells enriched with complex, 
highly branched surface N-glycans, referred to here as N-glyhi cells. Binding of 
fluorochrome-conjugated lectins to cells was determined by counting the “brightness” of 
cells in Tif images.  Results showed that the mean values for ConA binding to CAL27 
and HSC-3 cells were 14.3 and 10.3 fluorescence intensity, respectively, indicating 
increased ConA binding to CAL27. On the other hand, binding PHA-L was reduced for 
CAL27 cells 13.8 and greater for HSC cells 14.4 (Fig. 4).  Collectively, these results 
showed that HSC-3 cells exhibited increased binding of the PHA lectin suggesting that 
they had more complex N-glycans at their cell surface compared to CAL27 cells, while 
CAL27 cells displayed higher binding of ConA most likely due to greater modification 
with high-mannose/hybrid N-glycoans.  (Fig 4).  
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Fig. 4. Immunofluorescence localization of PHA and ConA lectins in CAL27 and HSC-3 cells. Results show 
increased surface expression of complex glycans in HSC-3 and greater expression of high mannose/hybrid 
glycans in CAL27 cells. Analysis of PHA and ConA lectin localization was carried out with Tif images using 
ImageJ software (Schneider, Rasband, & Eliceiri, 2012),. After background subtraction, all settings were fixed 
to the most highly stained sample and all other images were acquired at those settings.	
 
							CAL27		 	 	 HSC-3		
							Con
A 
 	
													
							PH
A	
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HSC-3 cells are hypersensitive to the GPT inhibitor, tunicamycin  
Our published studies have shown that in homeostatic cells, DPAGT1/Wnt/β-catenin/E-
cadherin network maintains a balance between cell proliferation and cell adhesion 
(Sengupta et al, 2013).  In OSCC, this network is deregulated, leading to the loss of E- 
cadherin mediated negative feedback mechanism, which allows  DPAGT1-Wnt/β-catenin 
positive  feedback loop to become amplified  and to operate without negative  controls 
(Sengupta et al., 2013; Jamal et al., 2012). Thus, we postulated that  this scenario would 
render OSCC  cell hypersensitive to tunicamycin.  Tunicamycin is an antibiotic inhibitor 
of GPT that causes cell death in all cellular system examined to date (Lehle and Tanner 
1976; Heifetz et al. 1979). We tested this hypothesis with  OSCC CAL27 and HSC-3 
cells, normal canine epithelial MDCK cells and  murine fibroblasts. Fibroblasts are the 
principal cell type found within the tissue matrix and they fulfill a number of critical 
functions including regulation of epithelial differentiation states by impacting cell-cell 
adhesion and through the release of growth factors (Kalluri & Zeisberg, 2006; Su, Sung, 
Beebe, & Friedl, 2012). They play a key role in tissue repair and the wound response and 
similarities between the healing process and tumor development have long been noted 
(Dvorak. 1986). Using Image J software (Schneider et al., 2012), cell Count was done 
manually (Table 2), and results showed that tunicamycin was most cytostoxic with HSC-
3 cells, followed by CAL27, and then MDCK cells, with fibroblasts displaying greatest 
resistance (Fig. 5). This susceptibility of cancer cells to tunicamycin emphasizes the 
importance of DPAGT1/N-glycosylation in cancer.  
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	 Control	
(#	of	cells	per	field)	
	
Tunicamycin	
(#of	cells	per	field)	
Percent	
Difference		
CAL27	 595	
	
446	
	
75%	
HSC-3	 477	 253	
	
53%	
MDCK	 501	
	
428	
	
85%	
Fibroblast	 450	
	
425	
	
94%	
Table	2.	Total	cell	count	of	CAL27,	HSC-3,	MDCK	and	3T3	Fibroblast	cells	without	and	with	tunicamycin	treatment	
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	 Control	
(#	of	cells	per	field)	
	
Tunicamycin	
(#of	cells	per	field)	
Percentage	
CAL27	 595	
	
446	
	
75%	
HSC-3	 477	 253	
	
53%	
MDCK	 501	
	
428	
	
85%	
Fibroblast	 450	
	
425	
	
94%	
Fig. 5. Comparison of tunicamycin sensitivity of CAL27 and HSC-3 cells with MDCK cells and fibroblasts. 
Immunofluorescence localization of PHA-bound surface N-glycans using epifluorescence microscope with the 
SPOT Digital Microscope Camera Software and Image J software for cell counting. 
						CAL	27	20x	 	 							HSC-3	20x	 	 		MDCK	20x	 	 								Fibroblast	20x	
0.5g/m
l	
Contro
l	
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HSC-3 cell-driven tumor xenografts in nude mice are inhibited by tunicamycin.  
To determine the role of DPAGT1 in tumor growth and metastasis, we carried out initial 
studies with the orthotopic nude mouse model of OSCC of the tongue. We hypothesized, 
that if DPAGT1 was one of the key contributors to OSCC pathogenesis, treatment of 
HSC-3-driven tumors with tunicamycin would interfere with their growth and metastasis. 
Indeed, although some metastases were detected in tunicamycin-treated mice, they were 
significantly less severe compared to the control animals (Fig. 8 and 9). Furthermore, 
caliper measurements of tongue tumor volumes following treatment with tunicamycin 
confirmed that they were smaller in size. Thus, inhibition of DPAGT1 expression was 
associated with reduced HSC-3 xenografts tumor growth and metastasis, suggesting that 
DPAGT1 contributes to OSCC progression.  
  
 
 
 
 
 
 
 
 
		 19	
 
 
 
 
 
 
 
 
 
  
Fig. 9. Caliper measurements of tongue tumors with and without 
tunicamycin treatment  
		 20	
Discussion 
These collective results provide further support for the importance of DPAGT1/N-
glycosylation in OSCC pathobiology. As the rate-limiting enzyme in the N-glycosylation 
pathway, GPT, promotes the activity of one of the main regulators of Wnt signaling, β–
catenin resulting in inappropriate activation of Wnt/β-catenin signaling (Varelas et al, 
2014). The Wnt/β-catenin pathway has been shown to be a key pathway defining the 
cancer initiating state in murine salivary gland tumors and in human head and neck 
cancers (Wend et al, 2013; Jamal et al, 2012; Varelas et al, 2014).  Further, protein N-
glycosylation has emerged as a central regulator of tissue hemostasis and its 
dysregulation has been associated with OSCC initiation and progression to aggressive 
disease (Jamal et al, 2012; Nita-Lazar et al, 2009; Liu et al, 2013). Thus, the association 
between Wnt/b-catenin signaling and protein N-glycosylation is likely to play a central 
role in OSCC pathobiology and in progression to advanced metastatic disease.   
The present study further highlights the role of a key N-glycosylation gene, 
DPAGT1, in OSCC aggressive properties by demonstrating its association with 
metastatic phenotypes likely to drive advanced disease. Specifically, modification of 
OSCC HSC-3 cells with highly branched complex N-glycans accompanies increased 
nuclear b-catenin, as well as HSC-3-cell derived tumor growth and metastatic properties 
in an orthotopic oral cancer nude mouse model. Further, HSC-3 cells exhibit hyper-
sensitivity to the GPT inhibitor, tunicamycin, in vitro and in vivo suggesting that  
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malignant OSCC cells have increased dependence on the N-glycosylation pathway. 
However, further investigations are suggested to test the cell viability with tunicamycin 
to confirm our results and role out any other factors that could influence survival of cells. 
Collectively, these studies further confirm the importance of protein N-glycosylation in 
modulating invasive properties of OSCC and suggest that targeting this metabolic 
pathway may represent an effective strategy for the treatment of this disease. 
 
 
 
.  
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